biOasis Technologies Ord Shs BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

GREY:BIOAF - Post by User

biOasis Technologies Ord Shs > They told you what they were going to do...

<< Previous

Bullboard Posts

Next >>

Comment by Boomskidon May 23, 2023 8:29pm

147 Views

Post# 35461110

RE:RE:They told you what they were going to do...

Garbage, poof. Denali's value was and remains dependent on TV, ETV and the therapeutics created with them.

If either Denali or Bioasis announced that they could successfully treat brain tumours, do you seriously think that the pharmaceutical industry industry and the markets would ignore that?

Would the market ignore the $7 billion in annual revenue that a BBB-penetrant version of Herceptin could bring in?

Even your precious S&P Biotech ETF would sit up and howl at the moon over that!

What is your agenda, poof, to post nonsense like that? Are you working for anybody we should know about?

jd

<< Previous

Bullboard Posts

Next >>

How Canadian investors can benefit from flow-through shares